Focusing on global hemophilia, metabolic diseases and anti-tumor fields

It was learned that the innovative drug research and development company “Shengsi Bio” announced the completion of the A and B rounds of financing of more than 800 million yuan. The B round of financing was led by Haitong Kaiyuan, Yifeng Capital and Huarong Rongde jointly participated in the investment, and the A round shareholders IDG Capital, Lianxin Capital, and Waige Capital continued to support the investment. The funds raised in this round will continue to support the company’s biomacromolecule drug R&D clinical, production workshop construction and commercial development. Yikai Capital has served as the exclusive financial advisor of Shengsi Biological in the series A and B financing of Shengsi Biological.

Shensi Biotechnology is engaged in the research and development of long-acting recombinant protein innovative drugs, mainly focusing on the unmet clinical needs in the fields of global hemophilia, metabolic diseases and anti-tumor. Based on the company’s protein expression platform and protein modification platform, develop recombinant long-acting and ultra-long-acting blood coagulation factor products (eight factors, nine factors and seven factors), with world-leading performance and safety, and are researching in the field of metabolic diseases Ultra-long-acting insulin, GLP-1 and other products, and PSMA and other products are under development in the anti-tumor field.

From the perspective of research and development progress, the long-acting recombinant blood coagulation eight-factor product independently developed by the company has entered the phase III clinical research phase, and the ultra-long-acting recombinant blood coagulation eight-factor product has been declared for clinical use. Wang Yali, CEO of Shengsi Biotech, said: “The company will successively apply for the listing of a number of new drugs, enter the clinical trial stage, enter or will enter the clinical application.” Dr. Zhang Xiao, Managing Director of Yikai Capital, said: “Two consecutive rounds of large-scale drugs in a short period of time. The successful completion of the financing will help the company’s first domestic long-acting reorganized eight-factor product to be produced, and will also provide financial support for the company’s global clinical trials of multiple products.”

Frost & Sullivan’s data shows that the global pharmaceutical market has grown rapidly, from approximately US$1100.5 billion in 2015 to US$1324.5 billion in 2019, with an average annual compound growth rate of 4.6%. It is expected to reach US$16395 billion by 2024, with a compound annual growth rate of 4.4% from 2019 to 2024. In the domestic market, national policies squeeze low-level imitations on the one hand, and on the other hand squeeze profit margins in the pharmaceutical circulation link. With the policy dividend, the scale of the innovative drug market has surged.

Zhang Xiangyang, Chairman of Haitong Kaiyuan, said: “The scientific research team led by Dr. Wang Yali of Shengsi Biotechnology has been researching in the fields of protein drug chemical modification for many years, and has focused on the development of drugs urgently needed by Chinese patients. A series of internationally competitive pipelines.”

Hu Haoyue, Investment Director of IDG Capital, said: “The Biotech team has been engaged in the research and development of long-acting biological products for a long time, and has a comprehensive and leading layout in the field of hemophilia. It is expected to be the first to be listed in China with long-acting recombinant blood coagulation factors. There are also many early innovative products in the field of oncology and oncology.”

In the subdivision of innovative drug research and development, macromolecular drugs have performed prominently in recent years, and antibody drugs with new targets and new mechanisms of action are emerging in an endless stream. The world’s top best-selling drug, bigMost of them are biomacromolecule drugs. In recent years, many domestic large-molecule drug research and development companies have successively listed on the market, such as Junshi Biology and Xinda Biology.